United Therapeutics Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Great. Good morning, everyone. My name is Jess Fye. I'm one of the senior biotech analysts at JPMorgan, and we're continuing the health care conference this morning with United Therapeutics. I'm joined by the company's CEO, Martine Rothblatt. And unlike in normal year where I'd send you down to the Yorkshire room for Q&A, this is going to move seamlessly into a Q&A after her presentation. If you want to participate in Q&A, there's a ask a question button on your screen. Just click on that. It sends the questions to a portal so that I can read them to management. But in the meantime, we can get started.
Let me pass it over to Dewey Steadman from IR, first.
Hey, good morning. Our remarks today may include forward-looking information about our business. And please see our SEC filings for risks and uncertainties that could cause actual results to differ. Also, Martine's presentation today is available as a PDF
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |